Gan Lu, Guo Xiaofei, Dong Shichao, Sun Chuan
Department of Pharmacy, Children's Hospital of Nanjing Medical University, Nanjing, Jiangsu, China.
Department of Pharmacy, The Second Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, China.
Front Pharmacol. 2025 May 26;16:1529375. doi: 10.3389/fphar.2025.1529375. eCollection 2025.
Cardiovascular diseases (CVDs) remain the leading cause of death worldwide, both in developed and developing countries. Despite the implementation of various measures in clinical practice that have shown certain curative effects, poor prognosis and irreversible pathological cardiac remodeling continue to limit the therapeutic effect of CVDs. There are still many new mechanisms worth exploring for the regulation of CVDs. Previous studies have highlighted the potential applicability of exosomes in CVDs, and significant research has been conducted in this area. In this review, we summarize the physiological mechanisms of exosomes and the basic research achievements in regulating CVDs via exosomal non-coding RNAs. We also discuss the limitations and prospects of exosome application in CVD treatment.
心血管疾病（CVDs）仍然是全球范围内发达国家和发展中国家的主要死因。尽管在临床实践中实施了各种已显示出一定疗效的措施，但预后不良和不可逆的病理性心脏重塑继续限制着心血管疾病的治疗效果。在心血管疾病的调控方面仍有许多新机制值得探索。先前的研究强调了外泌体在心血管疾病中的潜在适用性，并且已经在该领域进行了大量研究。在这篇综述中，我们总结了外泌体的生理机制以及通过外泌体非编码RNA调控心血管疾病的基础研究成果。我们还讨论了外泌体在心血管疾病治疗中的应用局限性和前景。
